, Question 1
A patient with a history of heart failure and reduced ejection fraction is
initiated on sacubitril/valsartan. Which pharmacodynamic mechanism best
explains the combined benefit of this therapy?
A. Inhibition of neprilysin increases natriuretic peptides, while valsartan
blocks angiotensin II receptors, reducing vasoconstriction and aldosterone
release.
B. Sacubitril inhibits angiotensin-converting enzyme, and valsartan
blocks angiotensin II receptors, leading to reduced bradykinin
degradation.
C. Sacubitril activates neprilysin to degrade natriuretic peptides, and
valsartan inhibits renin release, decreasing angiotensin II formation.
D. Sacubitril blocks angiotensin receptors, and valsartan inhibits
neprilysin, resulting in increased bradykinin and nitric oxide.
Correct Answer: A - Inhibition of neprilysin increases natriuretic
peptides, while valsartan blocks angiotensin II receptors,
reducing vasoconstriction and aldosterone release.
RATIONALE
Sacubitril inhibits neprilysin, the enzyme that degrades natriuretic
peptides, thereby increasing their levels and promoting vasodilation,
natriuresis, and diuresis. Valsartan blocks angiotensin II AT1
receptors, reducing vasoconstriction and aldosterone secretion. Option
B incorrectly states sacubitril inhibits ACE; C and D misassign
mechanisms.
Question 2
A patient with a CYP2C19 poor metabolizer genotype is prescribed clopidogrel
after percutaneous coronary intervention. Which alternative antiplatelet agent
is most appropriate to reduce the risk of stent thrombosis?
A. Prasugrel
Page 2
, B. Ticagrelor
C. Clopidogrel increased dose
D. Aspirin monotherapy
Correct Answer: A - Prasugrel
RATIONALE
Prasugrel and ticagrelor are not dependent on CYP2C19 activation and
are anticipated alternatives for poor metabolizers. Increasing
clopidogrel dose is contraindicated due to lack of efficacy and
bleeding risk. Aspirin monotherapy and cilostazol are nonessential as
they do not provide adequate P2Y12 inhibition post-PCI.
Question 3
A patient with severe sepsis is receiving vancomycin. The pharmacist
recommends AUC-guided dosing. Which parameter is most critical to monitor
to minimize nephrotoxicity while ensuring efficacy?
A. Trough concentration only
B. Peak concentration only
C. AUC/MIC ratio
D. Time above MIC
Correct Answer: C - AUC/MIC ratio
RATIONALE
AUC/MIC ratio is the pharmacodynamic target for vancomycin
efficacy and is correlated with clinical outcomes and nephrotoxicity.
Trough-only monitoring is less predictive of AUC and may lead to
suboptimal dosing. Peak and time above MIC are not primary
monitoring parameters for vancomycin.
Question 4
Which statement accurately describes the impact of a high-fat meal on the oral
bioavailability of a lipophilic drug with high first-pass metabolism?
Page 3
A patient with a history of heart failure and reduced ejection fraction is
initiated on sacubitril/valsartan. Which pharmacodynamic mechanism best
explains the combined benefit of this therapy?
A. Inhibition of neprilysin increases natriuretic peptides, while valsartan
blocks angiotensin II receptors, reducing vasoconstriction and aldosterone
release.
B. Sacubitril inhibits angiotensin-converting enzyme, and valsartan
blocks angiotensin II receptors, leading to reduced bradykinin
degradation.
C. Sacubitril activates neprilysin to degrade natriuretic peptides, and
valsartan inhibits renin release, decreasing angiotensin II formation.
D. Sacubitril blocks angiotensin receptors, and valsartan inhibits
neprilysin, resulting in increased bradykinin and nitric oxide.
Correct Answer: A - Inhibition of neprilysin increases natriuretic
peptides, while valsartan blocks angiotensin II receptors,
reducing vasoconstriction and aldosterone release.
RATIONALE
Sacubitril inhibits neprilysin, the enzyme that degrades natriuretic
peptides, thereby increasing their levels and promoting vasodilation,
natriuresis, and diuresis. Valsartan blocks angiotensin II AT1
receptors, reducing vasoconstriction and aldosterone secretion. Option
B incorrectly states sacubitril inhibits ACE; C and D misassign
mechanisms.
Question 2
A patient with a CYP2C19 poor metabolizer genotype is prescribed clopidogrel
after percutaneous coronary intervention. Which alternative antiplatelet agent
is most appropriate to reduce the risk of stent thrombosis?
A. Prasugrel
Page 2
, B. Ticagrelor
C. Clopidogrel increased dose
D. Aspirin monotherapy
Correct Answer: A - Prasugrel
RATIONALE
Prasugrel and ticagrelor are not dependent on CYP2C19 activation and
are anticipated alternatives for poor metabolizers. Increasing
clopidogrel dose is contraindicated due to lack of efficacy and
bleeding risk. Aspirin monotherapy and cilostazol are nonessential as
they do not provide adequate P2Y12 inhibition post-PCI.
Question 3
A patient with severe sepsis is receiving vancomycin. The pharmacist
recommends AUC-guided dosing. Which parameter is most critical to monitor
to minimize nephrotoxicity while ensuring efficacy?
A. Trough concentration only
B. Peak concentration only
C. AUC/MIC ratio
D. Time above MIC
Correct Answer: C - AUC/MIC ratio
RATIONALE
AUC/MIC ratio is the pharmacodynamic target for vancomycin
efficacy and is correlated with clinical outcomes and nephrotoxicity.
Trough-only monitoring is less predictive of AUC and may lead to
suboptimal dosing. Peak and time above MIC are not primary
monitoring parameters for vancomycin.
Question 4
Which statement accurately describes the impact of a high-fat meal on the oral
bioavailability of a lipophilic drug with high first-pass metabolism?
Page 3
